Amanda Chen (@_amandachen) profile picture

Postdoctoral researcher šŸ‘©šŸ»ā€šŸ”¬ | Porteus lab | @Stanford Previously: PhD student | Beavis lab | @PeterMacCC I ā¤ļø CRISPR, synthetic biology & cell therapies

Joined January 2020
Photo by Amanda Chen (@_amandachen)Photo by Amanda Chen (@_amandachen)Photo by Amanda Chen (@_amandachen)Photo by Amanda Chen (@_amandachen)Photo by Amanda Chen (@_amandachen)Photo by Amanda Chen (@_amandachen)
Excited to share that my PhD work is out in @Nature today! We engineered armoured CAR T cells to express therapeutic payloads only at the tumour site, to improve their safety and efficacy for the treatment of solid cancers. 1/14 nature.com/articles/s41586-0…
13
71
5
518
34,170
šŸ›”ļø Drs. @_AmandaChen, Kah Min Yap, Imran House, Phillip Darcy, and @PaulBeavis4 developed #CRISPR-edited armored CAR T cells that deliver cytokines directly to tumor sites. @Nature article: go.nature.com/3I8Nk8S Discussion: bit.ly/3Gu9UIF
1
3
14
1,089
Amanda Chen retweeted
Wow amazing work using NR4A2/RGS16 promoters to trigger IL‑12/IL‑2 only in tumors is brilliant! A big game‑changer in CAR‑T therapy. Huge congrats to @_amandachen and colleagues ! šŸŽ‰
1
1
674
This study highlights a novel application of our tumour-inducible expression system: extending the therapeutic lifespan of an armoured CAR T cell by restricting its enhanced effector functions to the tumour site. 4/5
1
1
342
Therefore, gene editing strategies that enable precise control of transgene expression will be key to designing more effective CAR T cells. Congratulations @kevin_sek, and thank you to everyone who contributed to this work! 5/5
300
Wow. Endogenous regulatory circuit-generated armoured CAR T cells. Seriously cool. Basic premise is to ā€œarmourā€ CAR T cells by getting them to express pro-inflammatory cytokines only when in tumours. Since T cells in tumours get exhausted and up-regulate PD1, the first approach was to knock in TNFα under the PD1 promoter. So when tumours try to switch off T cells… they actually switch them on! Such a cool concept. They tested other pro-inflammatory cytokines under PD-1 promoter-driven expression, and found most worked, except IL-12 under this promoter caused severe toxicity, because PD-1 expression outside the tumour seems to be too high. So then they screened for genes up-regulated in tumours versus spleen and picked out some top candidates whose knockout didn’t affect T cell function. They honed in on expressing IL-12 knocked into the NR4A2 locus, and expressing IL-2 knocked into the RGS16 locus. These worked unbelievably well. The team also developed a one-step knock-in protocol for knocking in both the CAR to the TRAC locus and the cytokine to the NR4A2/RGS16 locus. This is so awesome. Hopeful for the clinical trials in the future!
1
6
818
In the news today: Peter Mac scientists have developed ā€œPrecision Guided Munitionā€ CAR T-cells – smart immune cells that target solid tumours directly. In lab models, they wiped out breast, colon & ovarian tumours with cure rates near 100%! More: petermac.org/about-us/news-a…
12
1
31
3,765
Fresh off the press! ā™Øļø Scientists, including @_amandachen & @paulbeavis4, developed a #CRISPR knock-in strategy that leverages the regulatory mechanisms of endogenous genes to drive transgene expression in a tumor-localized manner. @nature | go.nature.com/3I8Nk8S
1
1
677
NR4A2 & RGS16 promoters support delivery of cytokines (e.g. IL-12) directly to the tumor site, leading to enhanced antitumor efficacy and long-term survival of mice in both syngeneic and xenogeneic models @Nature @paulbeavis4 @_amandachen @emsderrick nature.com/articles/s41586-0…
1
12
2
39
3,343
And a special thank you to @v_wiebking_md (previously in the Porteus lab), who helped us establish our CRISPR/Cas9 + AAV6 protocol and got me through the first roadblock in my PhD! 13/14
1
4
483
Lastly, thank you to everyone in the Beavis and Darcy labs for all the help with our crazy, huge experiments. This work was truly a team effort, and I feel so lucky to have done a PhD in such a collaborative lab. 14/14
5
434